PLAU and neoplasm: Taken together, these data demonstrate for the first time that uPA-sEVs-siSrc may serve as a promising therapy to simultaneously target and eliminate senescent stromal cells and tumor cells, and to enhance the efficacy of chemotherapeutic agents in tumor regression.